¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor associated antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • virilizing tumor
    ³²¼ºÈ­Á¾¾ç
  • Wilms¡¯ tumor
    ºô¸§½ºÁ¾¾ç
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen competition
    Ç׿ø°æÀï
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö
  • antigen excess
    Ç׿ø°úÀ×
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • antigen mimicry
    Ç׿øÀ¯»ç¼º
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
  • antigen presentation
    Ç׿øÁ¦½Ã
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • stromal tumor
    ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • tumor stain
    Á¾¾çÁ¶¿µ
  • tumor cell survival
    Á¾¾ç¼¼Æ÷»ýÁ¸
  • tumor
    Á¾¾ç
  • teratodermoid tumor
    ±âÇüÀ¯ÇÇÁ¾
  • teratoid tumor
    ±âÇüÁ¾
  • tridermic tumor
    »ï¹è¿±Á¾¾ç
  • trophoblastic tumor
    ¿µ¾ç¸·Á¾¾ç
  • virilizing tumor
    ³²¼ºÈ­Á¾¾ç
  • virus-induced tumor
    ¹ÙÀÌ·¯½ºÀ¯¹ßÁ¾¾ç
  • Wilms' tumor
    Àª¸§ÁîÁ¾¾ç
  • antigen
    Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø
  • antigen competition
    Ç׿ø°æÀï
  • antigen excess
    Ç׿ø°úÀ×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • pregnancy tumor
    ÀÓ½ÅÁ¾¾ç(ìõããðþåË)
  • primary tumor
    ¿ø¹ßÁ¾¾ç(ê«Û¡ðþåË)
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç(ê«ã·ãêÌèèâÛÏç¨ðþåË)
  • pulmonary sulcus tumor
    Æó±¸Á¾¾ç(øËÏ­ðþåË)
  • ranine tumor =ranulus
    µÎ²¨ºñÁ¾¾ç(¡­ðþåË). µÎ²¨ºñÁ¾(¡­ðþ), Çϸ¶Á¾(ùÁØ©ðþ)
  • recurrent tumor
    Àç¹ß¼º Á¾¾ç(î¢Û¡àõðþåË)
  • renal pelvic tumor
    ½Å¿ìÁ¾¾ç
  • renal pelvic tumor
    ½Å¿ìÁ¾¾ç(ãìéâðþåË)
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñ¼º¹æ»ç±¸Ã¼Á¾¾ç
  • ABH antigen
    ABH Ç׿ø
  • B antigen
    B Ç׿ø(ù÷ê«)
  • B cell antigen
    B ¼¼Æ÷Ç׿ø
  • CA 19-9 antigen
    CA 19-9 Ç׿ø
  • CA 50 antigen
    CA 50 Ç׿ø
  • CA-2<>
    CA-2<<ÄÝ·ÎÀ̵åÇ׿ø>>
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antigen detection
    Ç׿ø°ËÃâ
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö(ù÷ê«üªß¤ßÈâ¦).
  • antigen drift
    Ç׿ø¼Òº¯ÀÌ.
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen mimicry
    Ç׿øÀ¯»ç¼º.
  • antigen modification
    Ç׿øº¯Çü.
  • antigen presentation
    Ç׿øÁ¦°ø, Ç׿øÀü´Þ, Ç׿øÁ¦½Ã
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen presenting cells
    Ç׿ø Àü´Þ ¼¼Æ÷
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • antigen recognition
    Ç׿øÀÎÁö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • tolerogenic antigen
    ³»¼º»ý¼º Ç׿ø (Ò±àõßæà÷ù÷ê«)
  • transplantation antigen
    ÀÌ½Ä Ç׿ø(ì¹ãÕù÷ê«)
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
  • V antigen
    V Ç׿ø(ù÷ê«)
  • Vi antigen
    Vi Ç׿ø (ù÷ê«)
  • virus antigen
    ¹ÙÀÌ·¯½º Ç׿ø (ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
AAN AIDS-associated nephropathy; alpha-amino nitrogen; American Academy of Neurology; American Academy o...
DAA decompensated autonomous adenoma; dementia associated with alcoholism; dialysis-associated amyloidos...
PAG periaqueductal gray [matter]; polyacrylamide gel; pregnancy-associated globulin; proliferation-assoc...
MTACR multiple tumor-associated chromosome region
CPA tumor Cerebello-Pontine Angle(¼Ò³ú±³°¢ºÎ) tumor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CLA Cutaneous Lymphocyte-associated Antigen
CTLA-4 Cytotoxic T lymphocyte associated antigen 4
E.B.N.A. E.B.V.-associated nuclear antigen
EBNA Epstein-Barr virus associated nuclear antigen
FOCMA Feline oncornavirus-associated cell membrane antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adrenal cortex tumor
    ºÎ½Å ÇÇÁú Á¾¾ç
  • amelanotic tumor
    ¹«¸á¶ó´Ñ Á¾¾ç
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • benign melanocytic tumor
    ¾ç¼º ¸á¶ó´Ñ ¼¼Æ÷Á¾
  • benign vascular tumor
    ¾ç¼º Ç÷°üÁ¾
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • bladder tumor
    ¹æ±¤ Á¾¾ç
    ¹æ±¤ º®ÀÇ °¢ Á¶Á÷¿¡ ¹ß»ýÇÏ´Â Á¾¾ç. À¯µÎÁ¾, ¼±Á¾, ±ÙÁ¾, ÇǺξçÁ¾, Áö¹æÁ¾, Ç÷°üÁ¾ µî ¾ç¼ºÀÎ °Í°ú ¾Ï, À°Á¾ µî ¾Ç¼ºÀÎ °ÍÀÌ ÀÖÀ¸¸ç, ¾à 10 %¸¸ÀÌ ¾ç¼ºÀÌ°í ´ëºÎºÐÀÌ ¾Ç¼ºÀ¸·Î ¹ß»ý ¿øÀÎÀº ºÒ¸íÀÌ´Ù. ƯÁ¤ ±âÈ£ À½·á³ª ¾à¹°ÀÇ Àå±â ¿¬¿ë µî¿¡ ÀÇÇÏ´Â °Í°ú ¾Æ´Ò¸°°è ¾àǰÀ» Ãë±ÞÇÏ´Â °øÀå ±Ù·ÎÀÚ¿¡°Ô¼­ º¸°Ô µÇ´Â Á÷¾÷ ¾ÏÀÌ ÁÖ¸ñµÇ°í ÀÖ´Ù. ¶ÇÇÑ ¹æ±¤ Á¾¾çÀº Áß³â ÀÌÈÄ¿¡ Àß ¹ß»ýµÇ¸ç ¿©ÀÚº¸´Ù ³²ÀÚ¿¡°Ô ¸¹´Ù. Ãʱâ Áõ¼¼´Â Ç÷´¢¸¦ º¸ÀÌ´Ù°¡ ÀúÀý·Î ¸ÜÀ¸¸ç, ÀÌ·± ÀÏÀÌ ¹Ýº¹µÇ´Â µ¿¾È¿¡ ¹æ±¤¿°, ½Å¿ì½Å¿°À» º´¹ßÇÏ¿© ¹è´¢Åë, ºó´¢, Ç÷³ó´¢¿Í ¿äÅëÀÌ ³ªÅ¸³­´Ù. ¶§·Î´Â ¹æ±¤ ¾È¿¡ ÀÀÇ÷ÀÌ »ý±â°í ¹æ±¤ Ãⱸ¿¡ Á¾¾çÀÌ »ý°Ü ¹è´¢ Àå¾Ö°¡ ¿À±âµµ ÇÑ´Ù. ¹æ±¤°æ °Ë»ç·Î Áø´ÜÇϸç, ħÀ±¼ºÀÌ °­ÇϹǷΠÁ¶±â Áø´Ü ¹× Á¶±â Ä¡·á°¡ ¹Ù¶÷Á÷ÇÏ´Ù. Ä¡·á¹ýÀ¸·Î´Â ¿©·¯ °¡Áö ºñ´¢±â°úÀû ¼ö¼ú¹ý°ú ¹æ»ç¼± ¿ä¹ýÀÌ ÀÖÀ¸¸ç, Á¾¾çÀÇ ¼º»ó°ú ȯÀÚÀÇ ¿¬·É ¹× Àü½Å »óÅ µî¿¡ µû¶ó¼­ ÀÌ µÎ °¡Áö¸¦ Àû´çÈ÷ ¼¯¾î Ä¡·áÇÏ´Â Ä¡·á¹ýÀ» »ç¿ëÇÑ´Ù. ¾Ç¼ºÀÎ °æ¿ì ¹æÄ¡Çϸé ÇÒ¼ö·Ï ¹æ±¤ÀÇ ÁÖº¯ ¹× ¸Ö¸® ¶³¾îÁø ºÎÀ§¿¡µµ ÀüÀÌÇÏ¿© Ä¡À¯µÇ±â ¾î·Á¿öÁø´Ù. Àç¹ßÇϱ⠽¬¿î ÁúȯÀ̹ǷΠġ·á ÈÄ¿¡µµ 1³â¿¡ 3ȸ Á¤µµ ¹Ý¿µ±¸ÀûÀ¸·Î Á¤±â °ËÁøÀ» ¹Þ¾Æ¾ß Çϸç, Ç÷´¢°¡ ³ªÅ¸³ª¸é Áï½Ã ÁøÂûÀ» ¹Þµµ·Ï ÇÑ´Ù.
  • bluish tumor
    Ǫ¸¥ »ö Á¾¾ç
  • bone tumor
    °ñ Á¾¾ç
    óÀ½¿¡ »À¿¡ ¹ß»ýÇÏ´Â Á¾¾ç. ´Ù¸¥ ºÎÀ§¿¡¼­ ¾ÏÀÌ ÀüÀÌÇÏ´Â Àϵµ ÀÖÀ¸³ª, ´ëºÎºÐÀº Á¶°ñ¼¼Æ÷³ª Á¶Á÷ÀÇ ÀÌ»ó Áõ½Ä¿¡ ÀÇÇÏ¿© »ý±ä´Ù. °ñ Á¶Á÷ ÀÚü¿¡¼­ ¹ß»ýÇÏ´Â Á¾¾çÀ¸·Î´Â °ñÁ¾, ¿¬°ñÁ¾ÀÌ ÀÖ°í, »À¿¡ Æ÷ÇÔµÈ °áÇÕÁ¶Á÷¿¡¼­ ¹ß»ýÇÏ´Â ¼¶À¯Á¾, Ç÷°ü¿¡¼­ ¹ß»ýÇÏ´Â Ç÷°üÁ¾, °ñ¼ö¿¡¼­ ¹ß»ýÇÏ´Â °ñ¼öÁ¾ÀÌ ÀÖ´Ù. °ñ¼öÁ¾À» Á¦¿ÜÇϰí´Â ¸ðµÎ ¾ç¼º Á¾¾çÀ¸·Î »ý¸íÀÇ À§ÇèÀÌ µû¸£´Â ÀÏÀº ¾ø°í °ÅÀÇ Å¸°¢ ¼Ò°ß
  • brenner tumor
    ºê·»³Ê Á¾¾ç
    µå¹® ³­¼Ò Á¾¾çÀÌ´Ù. ¾î¸°ÀÌ¿¡¼­ ³ëÀαîÁö ¸ðµç ¿¬·É¿¡ ¹ß»ýµÇ³ª ´ëºÎºÐÀÌ 50¼¼ ÀÌÈÄ¿¡ »ý±ä´Ù. À°¾ÈÀûÀ¸·Î ´ëºÎºÐ °íÇü¼ºÀÌ°í ´Ü´ÜÇÏ¸ç ¼è¹é»öÀ̳ª µå¹°°Ô ÀÛÀº ³¶¼º ºÎÀ§°¡ Àְųª ¿ÏÀüÇÑ ³¶¼ºÀÏ ¼öµµ ÀÖ´Ù. Å©±â´Â 1cm ¹Ì¸¸ÀÇ ÀÛÀº Á¾¾ç¿¡¼­ ¸Å¿ì Å« Á¾¾ç±îÁö ´Ù¾çÇÏÁö¸¸ ´ë°³´Â Á÷°æ 2-8cmÀÌ´Ù. Çö¹Ì°æÀûÀ¸·Î »óÇÇ ¼¼Æ÷¿Í °£Áú ¼¼Æ÷·Î ±¸¼ºµÇ¾î ÀÖ°í »óÇÇ ¼¼Æ÷´Â ¾ãÀº È£»ê¼º ¼¼Æ÷Áú°ú Ÿ¿øÇü ¼¼Æ÷ÇÙÀ» °®´Âµ¥ Ư¡ÀûÀÎ ¼¼Æ÷ÇÙÀÇ "±¸" Áï "Ä¿ÇÇ ¾Ë" ¸ð¾çÀ» ÇÏ°Ô µÈ´Ù. °£Áú ¼¼Æ÷´Â ³­Æ÷¸· ¼¼Æ÷¸¦ ´à±âµµ ÇÑ´Ù. ´Ù¸¥ Á¾¾ç ƯÈ÷ Á¡¾×¼º ³¶¼±Á¾À̳ª ³¶¼º ±âÇüÁ¾°ú ÇÔ²² ¹ß»ýÇÏ´Â °ÍÀÌ Àß ¾Ë·ÁÁ® ÀÖ´Ù.
  • broad based tumor
    ±âÀúºÎ°¡ ³ÐÀº Á¾¾ç
  • calcified epithelial odontogenic tumor
    ¼®È¸È­ »óÇǼº Ä¡¼º Á¾¾ç
  • carotid body tumor
    °æµ¿¸Æ ¼Òü Á¾¾ç
  • cartilaginous tumor
    ¿¬°ñ¼º Á¾¾ç
    Á¶ÀýÇÒ ¼ö ¾øÀ» Á¤µµ·Î °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿­¿¡ ÀÇÇÑ ¿¬°ñ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
antigen-combining site See: paratope.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
antigen p150,95 A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
antigen presentation A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen presenting cell A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen-presenting cells Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation.
(12 Dec 1998)
antigen processing Modification of an antigen by accessory cells. This usually involves endocytosis of the antigen and either minimal cleavage or unfolding. The processed antigen is then presented in modified form by the accessory cell.
(18 Nov 1997)
antigen-responsive cell A small lymphocyte that, although not itself an immunologically activated cell, responds to antigenic (immunogenic) stimulus by a process of division and differentiation that results in the production of immunologically activated cells.
Synonym: antigen-responsive cell.
(05 Mar 2000)
antigen-sensitive cell A small lymphocyte that, although not itself an immunologically activated cell, responds to antigenic (immunogenic) stimulus by a process of division and differentiation that results in the production of immunologically activated cells.
Synonym: antigen-responsive cell.
(05 Mar 2000)
antigen shift Abrupt change in antigens expressed by a species or variety of organisms. Usually seen in microorganisms where the change may allow escape from immune recognition. Antigenic drift is a more gradual change.
See: antigenic variation.
(18 Nov 1997)
antigen unit The smallest amount of antigen that, in the presence of specific antiserum, will fix 1 complement unit.
(05 Mar 2000)
aspergillus antigen skin test <investigation> An antigen, prepared from aspergillus, is injected into the skin. In 48 to 72 hours the site is read as positive or negative. A positive skin test (inflammation at the test site) indicates prior exposure to aspergillus and therefore a risk for developing aspergillosis.
(27 Sep 1997)
Au antigen Auberger blood group
Aus antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á